ArticleJournal of neuro-oncology2025
Combined effects of escitalopram and vitamin E on phoenixin-20 secretion and neuroregulatory mechanisms in glioblastoma cells: a neuro-nutritional perspective.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanism of GPR173-Mediated Suppression of TNBC Proliferation and Metastatic Potential via GnRHR Upregulation.Clinical Medicine Insights. Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveGlioblastoma multiforme (GBM) is one of the most aggressive brain tumors, characterized by limited treatment options due to the blood-brain barrier and drug resistance. Escitalopram (Citoles), a selective serotonin reuptake inhibitor (SSRI), has recently attracted attention for its potential anti-tumor properties. This study aimed to evaluate the effects of Citoles and vitamin E on GBM cell viability, Phoenixin-20 (PNX-20) secretion, and their molecular interaction with the GPR-173 receptor.
methodsU87-MG glioblastoma cells were treated with various concentrations of Citoles and vitamin E, both individually and in combination. Cell viability was assessed using Trypan Blue exclusion and MTT assays. PNX-20 secretion was quantified via ELISA, and the binding potential of the compounds with GPR-173 was examined through in silico molecular docking analysis.
resultsThe combination treatment significantly reduced cell viability. ELISA results indicated that PNX-20 secretion increased markedly at 48 and 72 h post-treatment. Molecular docking analysis revealed that both compounds exhibited high binding affinity to the GPR-173 receptor, supporting their potential mechanisms of action.
conclusionThe combined use of Citoles and vitamin E demonstrated antiproliferative effects on GBM cells and significantly enhanced PNX-20 secretion, suggesting a meaningful neuropeptidergic response. These findings highlight the therapeutic potential of SSRIs in bridging neuroregulation and cancer biology.
Indexed as
Identifiers
40705198What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.